# US 2019/0316083 A1 · Culture method for long-term maintenance and proliferation subculture of human hepatocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316083 A1
- Document ID: US20190316083A1
- Status: Published application
- Kind: A1
- Application number: 16/455,578
- Filed: 2019-06-27
- Published: 2019-10-17
- Earliest claimed: 2014-05-30
- Assignees: The Second Military Medical University Affiliated Eastern Hepatobilary Surgery Hospital
- Applicants: The Second Military Medical University Affiliated Eastern Hepatobilary Surgery Hospital
- Inventors: Peilin ZHANG; Hongyang WANG
- Web page: https://patentgrep.com/patent/US20190316083A1

## CPC

- C12N 5/067: {Hepatocytes}
- C12N 5/0018: {Culture media for cell or tissue culture (media for specific animal cell type C12N5/06)}
- C12N 2501/11: Epidermal growth factor [EGF]
- C12N 2501/115: Basic fibroblast growth factor (bFGF, FGF-2)
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/135: Platelet-derived growth factor [PDGF]
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/235: Leukemia inhibitory factor [LIF]
- C12N 2501/237: Oncostatin M [OSM]
- C12N 2501/39: Steroid hormones
- C12N 2501/727: Kinases (EC 2.7.)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method for culturing hepatocytes involves maintenance, proliferation, and passaging of the hepatocytes. The method includes culturing the hepatocytes in a culture medium, which includes a hepatocyte basic medium; CHIR99021, which is a GSK-3 beta inhibitor at a concentration of 0.5-10 μM, SB 431542 or A83-01, which are RGF beta inhibitors, at a concentration of 0.5-10 μM, N-acetyl-cysteine at a concentration of 0.25-25 mM; and Oncostatin M at a concentration of 1-100 ng/mL There is no exogenous gene introduced into the hepatocytes, and the genetic background of the hepatocytes is not changed.

## Claims

### Claim 1

A method for culturing hepatocytes, involving maintenance, proliferation, and passaging thereof, wherein the method comprising:
culturing hepatocytes by a culture medium,
wherein said culture medium comprises:
a hepatocyte basic medium;
a GSK-3 beta inhibitor at a concentration of 0.5-10 μM, said GSK-3 beta inhibitor is CHIR99021;
a TGF beta inhibitor at a concentration of 0.5-10 μM, said TGF beta inhibitor is SB 431542 or A83-01;
N-acetyl-cysteine at a concentration of 0.25-25 mM; and
Oncostatin M at a concentration of 1-100 ng/mL,
wherein there is no exogenous gene being introduced into the hepatocytes, and the genetic background of the hepatocytes is not changed.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the method for culturing hepatocytes comprises:
(1) backing a culture plate for 1 to 24 hours; mixing and suspending primary hepatocytes in an adherent culture; plating; and incubating at 37° C. for 1 to 12 hours;
(2) discarding the adherent culture used in (1) above, transferring the hepatocytes into the culture medium of claim 1, and culturing the hepatocytes.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the hepatocyte basic medium is supplemented with 10% serum.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the concentration of GSK-3 beta inhibitor is 1-4 μM, and the concentration of TGF beta inhibitor is 1-8 μM.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the concentration of N-acetyl-cysteine is 0.5-12.5 mM.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the concentration of Oncostatin M is 5-80 ng/mL.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the culture medium further comprises an ingredient selected from the group consisting of:
human epidermal growth factor at a concentration of 5-100 ng/ml;
human fibroblast growth factor at a concentration of 5-100 ng/ml;
human hepatocyte growth factor at a concentration of 5-100 ng/ml;
dexamethasone at a concentration of 0.05-1 μM;
platelet derived factor at a concentration of 1-100 ng/ml; and
triiodothyronine at a concentration of 1-100 ng/ml.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the culture medium further comprises sodium pyruvate.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the hepatocytes are human hepatocytes.
